WEX Inc. (WEX) Forms $157.42 Double Top; Last Week Abbott Laboratories (ABT) Analysts

WEX Inc. (WEX) formed double top with $163.72 target or 4.00% above today’s $157.42 share price. WEX Inc. (WEX) has $6.77B valuation. The stock increased 0.01% or $0.01 during the last trading session, reaching $157.42. About 373,776 shares traded or 1.14% up from the average. WEX Inc. (NYSE:WEX) has risen 13.96% since March 8, 2017 and is uptrending. It has underperformed by 2.74% the S&P500.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. As per Tuesday, January 2, the company rating was upgraded by Morgan Stanley. The company was initiated on Thursday, August 17 by Citigroup. The firm has “Equal-Weight” rating given on Monday, January 4 by Morgan Stanley. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by RBC Capital Markets on Wednesday, January 24. The firm earned “Overweight” rating on Thursday, April 20 by Barclays Capital. The firm has “Buy” rating by RBC Capital Markets given on Friday, September 1. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) rating on Friday, September 22. Stifel Nicolaus has “Buy” rating and $58.0 target. The firm earned “Buy” rating on Tuesday, October 10 by Jefferies. The firm has “Neutral” rating by JP Morgan given on Friday, October 6. RBC Capital Markets maintained the shares of ABT in report on Monday, June 26 with “Buy” rating. See Abbott Laboratories (NYSE:ABT) latest ratings:

30/01/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $59 New Target: $64 Maintain
30/01/2018 Broker: Argus Research Rating: Buy New Target: $80.0
25/01/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $66 New Target: $70 Maintain
25/01/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $65 New Target: $69 Maintain
25/01/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $67 New Target: $70 Maintain
24/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $67.0 Maintain
25/01/2018 Broker: Wells Fargo Rating: Outperform Old Target: $66 New Target: $70 Maintain
25/01/2018 Broker: William Blair Rating: Buy Upgrade
25/01/2018 Broker: Guggenheim Rating: Buy New Target: $72.0 Maintain
24/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $70.0 Maintain

Investors sentiment decreased to 1.25 in Q3 2017. Its down 0.77, from 2.02 in 2017Q2. It dived, as 21 investors sold WEX Inc. shares while 40 reduced holdings. 24 funds opened positions while 99 raised stakes. 46.62 million shares or 2.64% more from 45.42 million shares in 2017Q2 were reported. Oak Ridge Ltd Llc holds 1.36% of its portfolio in WEX Inc. (NYSE:WEX) for 297,968 shares. Junto Capital Mgmt Ltd Partnership holds 305,788 shares or 2.81% of its portfolio. 3,045 were reported by Ls Investment Limited Liability Company. State Treasurer State Of Michigan holds 0.01% in WEX Inc. (NYSE:WEX) or 15,000 shares. Goldman Sachs Group Inc stated it has 204,459 shares. Hightower Advisors Limited Com has invested 0% in WEX Inc. (NYSE:WEX). Natixis holds 0.01% or 4,899 shares in its portfolio. Glenmede Na invested in 3,518 shares or 0% of the stock. Ameriprise Fincl accumulated 0.01% or 118,650 shares. Btim Corporation owns 103,305 shares. 3,361 are owned by Barclays Public Ltd. Atlantic Tru Group Limited Co accumulated 0.04% or 87,685 shares. Commonwealth Of Pennsylvania School Empls Retrmt invested 0.01% of its portfolio in WEX Inc. (NYSE:WEX). Teacher Retirement Systems Of Texas holds 3,184 shares or 0% of its portfolio. Envestnet Asset Mngmt owns 6,581 shares.

Among 19 analysts covering WEX (NYSE:WEX), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. WEX has $180.0 highest and $2 lowest target. $125.24’s average target is -20.44% below currents $157.42 stock price. WEX had 64 analyst reports since August 14, 2015 according to SRatingsIntel. As per Thursday, February 22, the company rating was maintained by Barclays Capital. Deutsche Bank upgraded WEX Inc. (NYSE:WEX) on Monday, June 5 to “Buy” rating. Oppenheimer maintained the stock with “Outperform” rating in Tuesday, February 9 report. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, October 11 report. The firm has “Buy” rating by SunTrust given on Tuesday, October 17. Keefe Bruyette & Woods maintained the shares of WEX in report on Sunday, August 13 with “Buy” rating. The firm earned “Hold” rating on Monday, September 21 by Deutsche Bank. The stock has “Neutral” rating by Credit Suisse on Monday, October 31. The stock of WEX Inc. (NYSE:WEX) earned “Hold” rating by Topeka Capital Markets on Thursday, October 29. The firm earned “Neutral” rating on Friday, June 24 by SunTrust.

Investors sentiment increased to 0.91 in Q3 2017. Its up 0.04, from 0.87 in 2017Q2. It increased, as 47 investors sold Abbott Laboratories shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Moreover, Sabal Trust has 0.06% invested in Abbott Laboratories (NYSE:ABT) for 11,470 shares. Voya Invest Management Lc has invested 0.1% of its portfolio in Abbott Laboratories (NYSE:ABT). Parsons Cap Ri has invested 0.73% in Abbott Laboratories (NYSE:ABT). Bradley Foster And Sargent Inc Ct stated it has 0.87% of its portfolio in Abbott Laboratories (NYSE:ABT). Checchi Cap Advisers stated it has 13,698 shares or 0.07% of all its holdings. America First Investment Ltd Liability Company holds 256,157 shares or 4.91% of its portfolio. Connors Investor Svcs has 1.57% invested in Abbott Laboratories (NYSE:ABT) for 194,860 shares. 11,865 are held by Arrow Corp. First Financial Bank Of Omaha owns 94,768 shares or 0.31% of their US portfolio. Proshare Advsr Ltd Liability reported 1.37 million shares. Northeast Fincl Consultants invested 0.08% of its portfolio in Abbott Laboratories (NYSE:ABT). Private Asset holds 655 shares. Mariner Wealth Advsrs Lc has invested 0.06% in Abbott Laboratories (NYSE:ABT). Mark Sheptoff Planning Limited stated it has 44,474 shares. Amica Pension Fund Board Of Trustees has 93,592 shares.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $107.03 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 227.84 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.